Business context and reporting period
Filing identity: The supplied filing is TRxADE HEALTH, Inc. (Nasdaq: MEDS), not Scienture Holdings, Inc. It is an unaudited Form 10-Q for the quarter ended September 30, 2022, filed November 7, 2022. The company operates a pharmaceutical marketplace, wholesale and retail pharmacy businesses, telehealth offerings, and SOSRx, a 51%-owned pharmaceutical marketplace venture.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $2.40 million | $2.55 million | $8.92 million | $7.50 million |
| Gross profit | $1.40 million | $1.28 million | $3.91 million | $3.51 million |
| Gross margin | 58% | 50% | 44% | 47% |
| Net loss | $529,000 | $1.30 million | $2.61 million | $4.53 million |
| Basic and diluted loss per share | $(0.06) | $(0.16) | $(0.31) | $(0.56) |
| Operating cash flow | Not stated separately | Not stated separately | $(2.76) million | $(2.14) million |
- At September 30, cash was $322,000, down from $3.12 million at December 31, 2021. Working capital was $312,000, versus $3.45 million at year-end 2021.
- Total assets were $4.69 million; total liabilities were $3.33 million; stockholders’ equity was $1.36 million. Current liabilities included $167,000 of related-party notes and $542,000 of contingent funding liabilities. Related-party notes totaled $500,000, including $333,000 classified long term.
- Nine-month investing cash outflow was $313,000, primarily for capitalized software. Financing provided $268,000, including proceeds from sales of future receivables. Cash decreased by $2.80 million over the period.
Changes versus comparable periods
- Q3 revenue declined 5.9% year over year, while gross profit rose 9.4% and gross margin expanded to 58%. Management attributed the margin improvement partly to the platform’s revenue, which has no cost of goods, and improved Trxade Prime margins.
- Nine-month revenue increased 18.9%, but gross margin declined to 44% from 47%, reflecting product mix and earlier-period wholesale costs.
- Net losses narrowed in both comparisons. Management cited lower operating expenses and prior-year charges, including $1.2 million of inventory-investment losses and $630,000 of bad-debt expense in 2021. Q3 2022 also benefited from a $164,148 credit related to the GSG settlement.
- Trxade Prime reduced Q3 processed sales, units, and orders by 28%, 35%, and 23%, respectively, while management prioritized overhead reduction and margin improvement. Platform registered users exceeded 14,100, up 9% year over year.
Outlook, risks and unusual items
- Going concern: Management concluded substantial doubt exists about the company’s ability to continue as a going concern, citing limited resources, $322,000 cash, and the need for additional capital. It stated that without financing, meeting funding requirements over the next 12 months is unlikely.
- Management estimated approximately $6 million of operating expenses and working-capital requirements for October 2022 through September 2023, and described cost reductions, including an approximately $1 million annual reduction in salary and wages. No revenue or profitability guidance was provided.
- After quarter-end, the company closed an offering on October 7, 2022, raising approximately $1.75 million gross and $1.5 million net. The transaction included common shares, pre-funded warrants, and warrants for up to 2.66 million shares, subject to stockholder approval and other terms; potential dilution is material.
- Nasdaq had notified the company that it did not meet the $2.5 million stockholders’ equity requirement. Nasdaq granted an extension requiring the company to evidence compliance by January 25, 2023; failure could lead to delisting.
- Two 2022 future-receivables transactions provided $825,000 gross funding in exchange for $1.188 million of future receivables, with an approximately 36% effective interest rate disclosed for the contingent liability. The agreements give the funder priority rights to receivables and contain default provisions.
- The company is exploring strategic alternatives for Bonum Health, Community Specialty Pharmacy, and Alliance Pharma Solutions, including a sale, spin-off, combination, financing, or wind-down. No final decisions were reported.
- An $875,000 advance for COVID-19 test kits remained recorded as a receivable after the vendor reported FDA concerns that the kits were misbranded and adulterated; the company expected a refund and considered collection possible without legal action.
- Other notable matters include a $743,000 GSG settlement payable in installments, a Malaysian supplier dispute affected by the supplier’s winding-up, and a prior $500,000 glove deposit subject to ongoing litigation. The company also disclosed an April 2022 email compromise that led to approximately $123,000 in fraudulent payments, later recovered through insurance.
- Disclosure controls were deemed ineffective, with material weaknesses in written accounting/reporting policies and period-end reporting controls. Management reported no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the filing entity: the document is TRxADE HEALTH, Inc. (MEDS), not Scienture Holdings, Inc.
- Review subsequent liquidity and financing, including the October offering, any further capital needs, and the terms and status of the future-receivables funding.
- Check whether Nasdaq’s stockholders’ equity requirement was satisfied by the stated deadline and whether listing status remains at risk.
- Track collection of the $875,000 test-kit receivable, GSG settlement installments, and developments in the supplier litigation.
- Assess the outcome of strategic reviews of the B2C businesses, progress on internal-control remediation, and any dilution from warrants or future equity issuance.